2CUREX — 2cureX AB Share News
0.000.00%
Last trade - 00:00- SEK12.00m
- SEK9.90m
Brief: 2Curex Signs Distribution Agreement With Omnigen Medical Products In Turkey
Brief: 2CureX Provides Commercial Goals For 2022
Brief: 2Curex Signs Distribution Agreement With Labormed In Slovenia
Brief: 2Curex Signs Distribution Agreement With Werfen
Brief: 2Curex Q2 Pretax Loss Widens To SEK 6.6 Million
Brief: 2Curex AB Reports Q1 Loss Before Tax SEK 2.2 Mln
Brief: 2Curex's Clinical Partner Presents Positive Results Of IndiTreat-Guided Clinical Trial
Brief: 2CureX's Clinical Trial Meets Primary Endpoint
Brief: 2Curex AB Reprts Q4 Loss Before Tax Of 2.8 Mln SEK Versus Loss Of 2.7 Mln SEK
Brief: 2cureX: Inditreat Selected To Multinational Ovarian Cancer Project
Brief: 2cureX Appoints Kenneth Graabek Johansen As New CFO
Brief: 2cureX Appoints New CEO
Brief: 2cureX Q3 Pre-tax Loss Narrows To SEK 1 Mln
Brief: 2CureX Q2 Pretax Loss Widens To SEK 3.6 Million
Brief: 2cureX Completes A Heavily Oversubscribed Directed Issue Of About SEK 40 Mln
Brief: 2cureX Gets Third Payment From The EU' Horizon 2020 SME- Instrument Program
Brief: 2cureX Establishes Collaboration With Scandion Oncology And Erasmus Medical Centre
Brief: 2Curex Signs New Distributor Agreement In Portugal
Brief: 2cureX Q1 Pretax Loss Narrows To SEK 1.2 Mln